Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients

Patrizia Vici, Laura Pizzuti, Teresa Gamucci, Domenico Sergi, Francesca Conti, Germano Zampa, Pietro Del Medico, Roy De Vita, Marcello Pozzi, Claudio Botti, Simona Di Filippo, Federica Tomao, Isabella Sperduti, Luigi Di Lauro, Patrizia Vici, Laura Pizzuti, Teresa Gamucci, Domenico Sergi, Francesca Conti, Germano Zampa, Pietro Del Medico, Roy De Vita, Marcello Pozzi, Claudio Botti, Simona Di Filippo, Federica Tomao, Isabella Sperduti, Luigi Di Lauro

Abstract

Purpose: Chemotherapy regimens containing anthracyclines and taxanes represent the landmark of neoadjuvant systemic therapy of breast cancer. In advanced breast cancer patients liposomal anthracyclines (LA) have shown similar efficacy and less cardiac toxicity when compared to conventional anthracyclines. We performed this retrospective analysis in order to evaluate the efficacy and tolerability of neoadjuvant regimens including LA outside of clinical trials in routine clinical practice.

Methods: Fifty operable or locally advanced, HER2 negative, breast cancer patients were retrospectively identified in 5 Italian cancer centres. Nineteen patients had received 4 cycles of non-pegylated liposomal doxorubicin (NPLD) and cyclophosphamide, followed by 4 cycles of docetaxel, every 3 weeks. In 25 patients the reverse sequence was employed, and a third subgroup of 6 patients received 4 cycles of NPLD/cyclophosphamide every 3 weeks followed by 4 cycles of weekly carboplatin and paclitaxel.

Results: We observed 10 pathological complete responses (pCR) (20.0%, 95%CI, 9% to 31%), and 35 (70%, 95%CI, 57.3% to 82.7%) partial responses (pPR), whereas no patients progressed onto therapy. In the small subset of triple negative tumors the pCR rate was 37.5%, and in tumors expressing ER and/or PgR it was 16.7%. A pCR rate of 26.5% was observed in tumors with high Ki-67, whereas in tumors with low Ki-67 only one (6.2%) pCR was observed (p=0.14). Treatments were well tolerated. The most common toxicities were myelosuppression and palmar-plantar erytrodysesthesia; 4 asymptomatic and transient LVEF decrease have been recorded, without any case of clinical cardiotoxicity.

Conclusions: NPLD-cyclophosphamide and taxanes sequential regimens were proven effective and well tolerated in breast cancer patients with contra-indication to conventional anthracyclines undergoing neoadjuvant chemotherapy, even outside of clinical trials in everyday clinical practice.

Keywords: Breast cancer; everyday clinical practice; neoadjuvant chemotherapy; non-pegylated liposomal doxorubicin; retrospective analysis.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Three-years relapse free survival.

References

    1. Kuerer HM, Newman LA, Smith TL. et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460–9.
    1. Angelucci D, Tinari N, Grassadonia A. et al. Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. J Cancer Res Clin Oncol. 2013;139:269–80.
    1. Bear HD, Anderson S, Brown A. et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.
    1. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006;11:574–89.
    1. Vici P, Viola G, Rossi S. et al. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment. Clin Ter. 2008;159:453–6.
    1. Thiery-Vuillemin A, Llombart-Cussac A, Chaigneau L. et al. Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact. Breast. 2011;20:46–9.
    1. Vici P, Brandi M, Giotta F. et al. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide [EC] versus docetaxel followed by EC in node-positive breast cancer. GOIM [Gruppo Oncologico Italia Meridionale] 9902 study: Ann Oncol. 2012;23:1121–9.
    1. Puhalla S, Mrozek E, Young D. et al. Randomized phase II adjuvant trial of dose-dense docetaxel before or after doxorubicin plus cyclophosphamide in axillary node-positive breast cancer. J Clin Oncol. 2008;26:1691–7.
    1. Piedbois P, Serin D, Priou F. et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide [T/EC], or the reverse sequence [EC/T], every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide [TEC] every 3 weeks. AERO B03 randomized phase II study. Ann Oncol. 2007;18:52–7.
    1. Von Hoff DD, Layard MW, Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91:710–7.
    1. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–79.
    1. Lao J, Madani J, Puértolas T. et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv. 2013;2013:456409.
    1. Fisher NG, Marshall AJ. Anthracycline-induced cardiomyopathy. Postgrad Med J. 1999;75:265–8.
    1. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993;19:197–228.
    1. Mladosievicova B, Urbanova D, Radvanska E, Slavkovsky P, Simkova I. Role of NT-proBNP in detection of myocardial damage in childhood leukemia survivors treated with and without anthracyclines. J Exp Clin Cancer Res. 2012;31:86.
    1. Roziakova L, Bojtarova E, Mistrik M. et al. Serial measurements of cardiac biomarkers in patients after allogeneic hematopoietic stem cell transplantation. J Exp Clin Cancer Res. 2012;31:13.
    1. Lopez M, Vici P, Di Lauro L. et al. Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol. 1998;16:86–92.
    1. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol. 2004;130:1–7.
    1. Maini CL, Sciuto R, Ferraironi A. et al. Clinical relevance of radionuclide angiography and antimyosin immunoscintigraphy for risk assessment in epirubicin cardiotoxicity. J Nucl Cardiol. 1997;4:502–8.
    1. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58:97–110.
    1. Rosati MS, Raimondi C, Baciarello G. et al. Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial [phase I-II] Ann Oncol. 2011;22:315–20.
    1. Curtit E, Nouyrigat P, Dohollou N. et al. Myotax: a phase II trial of docetaxel plus non-pegylated liposomal doxorubicin as first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines. Eur J Cancer. 2011;47:2396–402.
    1. Vici P, Colucci G, Giotta F. et al. A multicenter prospective phase II randomized trial of epirubicin/vinorelbine versus pegylated liposomal doxorubicin/vinorelbine as first-line treatment in advanced breast cancer. A GOIM study. J Exp Clin Cancer Res. 2011;30:39.
    1. O'Brien ME, Wigler N, Inbar M. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl [CAELYX/Doxil] versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15:440–9.
    1. Harris L, Batist G, Belt R. et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94:25–36.
    1. Batist G, Ramakrishnan G, Rao CS. et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–54.
    1. Chan S, Davidson N, Juozaityte E. et al. Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol. 2004;15:1527–34.
    1. Sparano JA, Makhson AN, Semiglazov VF. et al. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. J Clin Oncol. 2009;27:4522–9.
    1. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010;3:CD005006.
    1. Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012;1:10.
    1. Crivellari D, Gray KP, Dellapasqua S. et al. Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trial. Breast. 2013;22:130–7.
    1. Schmid P, Krocker J, Jehn C. et al. Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial. Ann Oncol. 2005;16:1624–31.
    1. Gogas H, Papadimitriou C, Kalofonos HP. et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin [Caelyx] and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol. 2002;13:1737–42.
    1. Antón A, Ruiz A, Seguí MA. et al. Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol. 2009;20:454–9.
    1. Antón A, Ruiz A, Plazaola A. et al. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol. 2011;22:74–9.
    1. Smith IC, Heys SD, Hutcheon AW. et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–66.
    1. von Minckwitz G, Raab G, Caputo A. et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676–85.
    1. Iwata H, Sato N, Masuda N. et al. Docetaxel followed by fluorouracil/epirubicin/ cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer. Jpn J Clin Oncol. 2011;41:867–75.
    1. Wu J, Li S, Jia W, Su F. Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137:1505–10.
    1. Kaufmann M, Hortobagyi GN, Goldhirsch A. et al. Recommendations from an international expert panel on the use of neoadjuvant [primary] systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24:1940–9.
    1. Saracchini S, Foltran L, Tuccia F. et al. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification. Breast. 2013;22:1101–7.
    1. Lotrionte M, Palazzoni G, Abbate A. et al. Cardiotoxicity of a non-pegylated liposomal doxorubicin-based regimen versus an epirubicin-based regimen for breast cancer: The LITE [Liposomal doxorubicin-Investigational chemotherapy-Tissue doppler imaging Evaluation] randomized pilot study. Int J Cardiol. 2013;167:1055–7.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj